April 3, 2025 11:14 AM EDT
Financing

PIPEs, bio­phar­ma’s fa­vorite fi­nanc­ing ve­hi­cle, freeze amid mar­ket strug­gles

Kyle LaHucik

Senior Reporter

PIPEs have fall­en out of fa­vor.

The pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, had one of the best years on record in 2024. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

Ab­b­Vie's im­munol­o­gy fran­chise re­mains a pow­er­house, as Skyrizi, Rin­voq com­bine for $5B

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times